Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

The Tumor Microenvironment

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

PRECISE-seq reveals disease-relevant TCR repertoires with phenotypic plasticity.

The Journal of experimental medicine·2026

Same author

Quadratus lumborum block at the lateral supra-arcuate ligament for postoperative analgesia: a protocol for a systematic review and meta-analysis.

Annals of medicine·2025

Same author

Vaccination Strategies and Research Gaps in Hepatitis E Virus for Special Populations.

Vaccines·2025

Same author

Machine Learning Models Based on Enlarged Chemical Spaces for Screening Carcinogenic Chemicals.

Chemical research in toxicology·2025

Same author

Freeze-drying enhances ToF-SIMS imaging of biological tissues <i>via</i> structural and metabolic preservation.

Analytical methods : advancing methods and applications·2025

Same author

Delta/Lambda Chirality: From Enantiomers to Diastereomers in Heterometallic Complexes with Chelating Ligands.

Inorganic chemistry·2025

Search research articles

Related Experiment Video

Updated: Jun 3, 2025

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

Multi-TACs: Targeting Solid Tumors with Multiple Immune Cell Co-engagers.

Yuxuan Zhang¹, Zijian Zhang², Feng Lin¹

¹Synthetic and Functional Biomolecules Center, Beijing National Laboratory for Molecular Sciences, Key Laboratory of Bioorganic Chemistry and Molecular Engineering of Ministry of Education, College of Chemistry and Molecular Engineering, Peking University, Beijing 100871, China.

ACS Chemical Biology

|January 9, 2025

Summary

This summary is machine-generated.

A new multimodal targeting chimera (Multi-TAC) platform uses a triple orthogonal linker (T-Linker) to co-engage multiple immune cells. This single-agent approach enhances tumor-targeted immunotherapy by managing the tumor-immune microenvironment (TIME).

More Related Videos

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

Enrichment and Characterization of the Tumor Immune and Non-immune Microenvironments in Established Subcutaneous Murine Tumors

Enrichment and Characterization of the Tumor Immune and Non-immune Microenvironments in Established Subcutaneous Murine Tumors

Published on: June 7, 2018

Related Experiment Videos

Last Updated: Jun 3, 2025

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

Enrichment and Characterization of the Tumor Immune and Non-immune Microenvironments in Established Subcutaneous Murine Tumors

Enrichment and Characterization of the Tumor Immune and Non-immune Microenvironments in Established Subcutaneous Murine Tumors

Published on: June 7, 2018

Area of Science:

Immunology
Oncology
Biotechnology

Background:

The tumor-immune microenvironment (TIME) comprises diverse immune cells that influence cancer immunotherapy outcomes.
Co-managing multiple immune cell types with a single agent is a significant challenge for advanced antitumor immunity.

Purpose of the Study:

To introduce a novel platform for simultaneously targeting multiple immune cell types within the TIME.
To enable single-agent-mediated, tumor-targeted co-engagement of immune cells for enhanced immunotherapy.

Main Methods:

Development of a triple orthogonal linker (T-Linker) based multimodal targeting chimera (Multi-TAC) platform.
Utilizing the Multi-TAC platform for coordinated targeting of various immune cell populations within the tumor microenvironment.

Main Results:

The Multi-TAC platform facilitates single-agent mediated co-engagement of multiple immune cells.
This approach allows for tumor-targeted immunotherapy by modulating the TIME.

Conclusions:

The T-Linker-based Multi-TAC platform offers a promising strategy for potentiating cancer immunotherapy.
This innovative approach addresses the challenge of synergistically co-managing multiple immune cells for improved antitumor responses.